Protrait

 

Manish Patankar, PhD
Professor
Director, Division of Reproductive Sciences; Associate Director of Endocrinology and Reproductive Physiology graduate program


Reproductive Sciences


Office Address
UW Hospital and Clinics
600 Highland Ave
Madison, WI, 53705


Administrative Assistant
Colleen Rohde-Szudy
crohde@wisc.edu
608-263-1209


Education

B.Sc. Chemistry, University of Bombay, India

M.Sc. Organic Chemistry, University of Bombay, India

M.S. Chemistry, Old Dominion University, Norfolk, VA

Ph.D. Biomedical Sciences, Old Dominion University and Eastern Virginia Medical School , Norfolk, VA

Post-Doctoral Fellowship Glycobiology and Reproductive Immunology, Eastern Virginia Medical School, Norfolk, VA


Honors and Awards

Member of National Institutes of Health special emphasis study section to evaluate U50 (SPORE) grant proposals

Member of National Institutes of Health special emphasis study section to evaluate U54 grant proposals

Member of National Institutes of Health special emphasis study section to evaluate grants submitted by members of the Cancer Immunopathology and Immunotherapy and Cancer Biomarkers study section

Member study section organized by the Institute for Clinical and Translational Research (ICTR), University of Wisconsin-Madison to evaluate pilot proposals.

Member of the Department of Defense study section for the Ovarian Cancer Research Program

Member of National Institutes of Health special study section to evaluate P01 and P50 proposals

Member of National Institutes of Health special study section to evaluate SPORE proposals

Member of National Institutes of Health special study section to evaluate Special Instrumentation grants


Memberships

American Association for Cancer Research

Patankar published in Cancers

Manish Patankar, PhD, director of the UW Ob-Gyn Division of Reproductive Sciences, has a new article published in the journal cancers.

Imaging Collagen Alterations in STICs and High Grade Ovarian Cancers in the Fallopian Tubes by Second Harmonic Generation Microscopy provides a new method of classification for fallopian tube cancers, and also quantifies the structural changes in the disease. In the study,

“...we couple SHG imaging of serous tubal intra-epithelial carcinomas (STICs), high-grade cancers, and normal regions of the fallopian tubes, using three distinct image analysis approaches to form a classification scheme based on the respective collagen fiber morphology. Using a linear discriminant analysis, we achieved near 100% classification accuracy between high-grade disease and the other tissues, where the STICs and normal regions were differentiated with ~75% accuracy. Importantly, the collagen in high-grade disease in both the fallopian tube and the ovary itself have a similar collagen morphology, further substantiating the metastasis between these sites.

You can read the whole paper here. Congratulations to Dr. Patankar and the rest of the publication team! 


Barroilhet awarded R01 grant!

Congratulations to Lisa Barroilhet, MD, of the UW Ob-Gyn Division of Gynecologic Oncology! Barroilet has been awarded her first Research Project Grant (R01) from the National Institutes of Health for the project "Repurposing Atovaquone for the Prevention of Ovarian Cancer."

This five-year award includes an innovative mouse model and a clinical trial on the effects of atovaquone on normal ovarian and fallopian tube tissue. Division of Reproductive Sciences Director Manish Patankar, PhD and Arvinder Kapur, PhD, were instrumental in the successful submission of this grant and will continue to be close collaborators.

Please congratulate Dr. Barroilhet, as well as Dr. Patankar and Dr. Kapur on this incredible accomplishment!


Patankar and Stanic labs publish in American Journal of Reproductive Immunology

An article in the American Journal of Reproductive Immunology was co-authored by researchers in the UW Ob-Gyn Divisions of Reproductive Sciences and Gynecologic Oncology! 

Identification of unique clusters of T, dendritic, and innate lymphoid cells in the peritoneal fluid of ovarian cancer patients” is a collaboration between members of the Patankar Lab and Stanic Lab, with clinical collaborators in the Division of Gynecologic Oncology. Co-authors include Division of Reproductive Sciences Director Manish Patankar, PhD, Aleks Stanic-Kostic, MD, PhD, Stanic Lab postdoctoral fellow Jessica Vazquez, PhD, Patankar Lab assistant scientist Arvinder Kapur, PhD, gynecologic oncologist Lisa Barroilhet, MD, and recently graduated resident Antonio Romo de Vivar Chavez, MD.

This work focuses on determination of the immune compartment in ovarian cancer ascites, an understudied but extremely important site for immune control of cancer spread. For the study, the Stanic Lab used their advanced immune monitoring platform using high-dimensional flow cytometry to examine the immunome of ascites specimens isolated, processed, characterized and cryopreserved by the Patankar Lab. Researchers identified novel immune cell clusters and demonstrated their association with pre-surgery CA-125 level, hinting at modulation of subsequent survival.

This work forms the basis of several projects and grant applications from Patankar and Stanic Labs and exemplifies the collaborative spirit of the Divisions of Reproductive Sciences and Gynecologic Oncology. 

Read the whole article here – congratulations to all co-authors!


Patankar co-authors publication in Analytical Chemistry

A recent publication by UW Ob-Gyn Division of Reproductive Sciences Director Manish Patankar, PhD was selected as an Editor’s Choice article in the journal Analytical Chemistry!

On-Tissue Derivatization with Girard’s Reagent P Enhances N-Glycan Signals for Formalin-Fixed Paraffin-Embedded Tissue Sections in MALDI Mass Spectrometry Imaging”, coauthored with the lab of Lingjun Li, PhD, of the UW-Madison School of Pharmacy, outlines a new way of treating and imaging tissue to analyze glycans, biomolecules with important implications for better understanding conditions like Alzheimer’s disease, diabetes, autoimmune diseases, and some types of cancer.

This study provides a promising approach to better understand the pathogenesis of cancer related aberrant glycosylation, which is beneficial to the design of improved clinical diagnosis and therapeutic strategies.

Read the whole study here. Articles are designated with Editors Choice status because of quality and broad public interest. What an exciting honor – amazing work, Dr. Patankar!


Patankar grad student Alharbi published in Scientific Reports

Research led by Yousef Alharbi, PhD, former graduate student in the lab of Division of Reproductive Sciences Director Manish Patankar, PhD, has been published in Scientific Reports!

Oxidative stress induced by the anti-cancer agents, plumbagin, and atovaquone, inhibits ion transport through Na+/K+-ATPase” was written in collaboration with Patankar, Bikash Pattnaik, PhD, of the UW SMPH Department of Pediatrics, Lisa Barroilhet, MD, of the UW Ob-Gyn Division of Gynecologic Oncology, and Arvinder Kapur, of the UW Ob-Gyn Division of Reproductive Sciences. 

In the study, Alharbi and co-authors found that plumbagin inhibits proliferation of human and mouse ovarian cancer cells:

“Recently we demonstrated that plumbagin was an effective anti-cancer agent and that its cytotoxic effect could be demonstrated across multiple cancer cell lines. Here, we extend these previous observations to further confirm the cytolytic activity of plumbagin against mouse (ID8) and human (SKOV-3, OVCAR-3, and TYKNu) high grade serous ovarian cancer cell lines. Our data demonstrate that irrespective of the cell line used, plumbagin was able to inhibit proliferation at an IC50 between 2.5 and 10 µM.”

Read the whole article here – congratulations to the research team!


Patankar publication featured on front page of journal Analyst

A study co-authored by UW Ob-Gyn Division of Reproductive Sciences Director Manish Patankar, PhD was featured on the front page of the journal Analyst!

Patankar and co-authors took on the study outlined in “Affinity-free enrichment and mass spectrometry analysis of the ovarian cancer biomarker CA125 (MUC16) from patient-derived ascites” to expand ovarian cancer diagnostic tools:

Developing a mass spectrometry-based assay for the ovarian cancer biomarker CA125 (MUC16) is a desirable goal, because it may enable detection of molecular regions that are not recognized by antibodies and are therefore analytically silent in the current immunoassay. Additionally, the ability to characterize the CA125 proteoforms expressed by individuals may offer clinical insight.

Read the whole article here!